Adocia
About
History
Management
Board of directors
Advisory board
Products and platforms
Pipeline
Technology Platforms
Careers
The « Adocians »
HR policy
Work environment
Join us
Partnering
Investors
Media
Contact
Contact us
Map and accessibility
Investors
Regulated information
Stock information
Corporate governance
General meeting
Media
Press releases
Media
EN
FR
ADOCIA Announces the Successful Phase 1 Study for BioChaperone® Lispro with Partner Tonghua Dongbao
Previous article
ADOCIA Announces its Participation at Upcoming Investor Conferences in January 2023
Next article
A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes. Diabetes Obes Metab., 2023;25(5):1241-1248.
